Mounjaro (tirzepatide) is a weekly shot that helps many people lose weight, but the price scares a lot of folks off. Here is the short version: the list price is high, yet most people never pay it. What you actually spend depends on your insurance, the brand you are prescribed, and which savings program you use. All figures below are as of mid-2026.
Mounjaro vs. Zepbound: this changes your price
This part trips up a lot of people, so read it first. Mounjaro is FDA-approved for type 2 diabetes. The same drug, tirzepatide, is sold under a different name, Zepbound, for weight loss. Same active ingredient, two brands, two approvals.
Why does that matter for cost? Insurance is much more likely to cover Mounjaro when you have a diabetes diagnosis. If you want the medication for weight loss and you do not have diabetes, most plans will not cover Mounjaro. In that case, Zepbound is usually the correct brand to ask your doctor and insurer about. Our Zepbound vs. Mounjaro guide breaks down the difference in plain terms.
The list price
Without insurance or any discount, Lilly lists Mounjaro at $1,112.16 per fill. Lilly counts one fill as a month's supply, which is four pens. That is the sticker price before any discount. For comparison, Zepbound lists at $499 to $1,086.37 per fill, depending on the product and the dose. The sections below cover insurance, savings cards and the manufacturer self-pay programs. What you pay depends on the product, dose, coverage and eligibility for any offer.
What insurance does and doesn't cover
If your plan covers Mounjaro for diabetes, your copay could be modest, sometimes $25 to $100 a month depending on the plan. For weight loss, coverage is spottier. Many commercial plans still exclude weight-loss drugs, though that is slowly changing. Read our guide to whether insurance covers GLP-1 weight loss, and check the GLP-1 insurance coverage guide for your specific carrier.
Medicare
Mounjaro is covered under standard Medicare Part D for diabetes. For obesity, there is bigger news: since July 1, 2026, a CMS demonstration called the Medicare GLP-1 Bridge has covered the Zepbound KwikPen and Wegovy for obesity at $50 a month. It is for eligible Part D enrollees and runs outside the normal Part D benefit. You are not eligible if you have type 2 diabetes. In that case your regular Part D plan may still cover a GLP-1 for diabetes, so ask about that route. The CMS eligibility criteria set out the rest. See our Medicare GLP-1 coverage guide for who is eligible.
The Lilly savings card
Eli Lilly offers a savings card that can bring your cost down a lot. If you have commercial insurance that covers Mounjaro for diabetes, you may pay as little as $25 per month. Zepbound has a similar card, also as low as $25 a month with commercial coverage. The card does not work with Medicare or Medicaid, so it mainly helps people with job-based or marketplace plans. You can run the numbers with our savings calculator.
LillyDirect self-pay
If you have no coverage, Lilly sells directly to patients. Mounjaro self-pay through LillyDirect starts at $499 a month, and that starting price is listed at every dose from 2.5 mg to 15 mg. You need a prescription and other terms apply, so check the current figure with LillyDirect before you budget on it. Zepbound through the same program is sold as a single-patient-use KwikPen or a 4-count single-dose vial, not the single-dose pen. The regular price for a 28-day supply is $299 at 2.5 mg, $399 at 5 mg, $499 at 7.5 mg, and $699 at 10 mg, 12.5 mg and 15 mg. A $449 purchase offer covers your first KwikPen fill at 7.5 mg or above, and it keeps applying only if each refill purchase is completed within 45 days of your previous delivery. That offer is for the KwikPen only, is capped at 11 fills a year, and ends December 31, 2026. Compare either route against clinic bundles on our GLP-1 pricing guide.
A note on compounded tirzepatide
You may see ads for cheap compounded tirzepatide. Be careful. The drug shortage that made mass compounding legal ended in early 2025, and on April 30, 2026 the FDA proposed excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list, the list of bulk ingredients that large outsourcing facilities may compound from (FDA announcement). That is a proposal about outsourcing facilities, not a ban on all compounding. Compounded versions are not FDA-approved and quality varies. Since the shortages ended, a state-licensed 503A compounding pharmacy may not regularly, or in inordinate amounts, make drugs that are essentially copies of a commercially available GLP-1, unless the prescriber determines and documents a significant difference for that individual patient (FDA guidance). Treat any bargain offer with skepticism and stick with the brand-name options above.
How to lower your cost
- Ask whether Zepbound, not Mounjaro, is the right brand for your situation. It can change what insurance approves.
- Check your plan's formulary before you fill anything.
- Apply for the Lilly savings card if you have commercial insurance.
- Compare LillyDirect self-pay if you are paying cash.
- Compare clinic prices, since bundles and consult fees vary widely.
Read more in our guide to finding affordable GLP-1 clinics and the Zepbound cost and savings guide.
Bottom line
Mounjaro's list price is high, but with insurance, the savings card, or LillyDirect, most people pay far less. The single biggest lever is getting the right brand for the right diagnosis. To compare real prices near you, search Mounjaro and tirzepatide clinics in our directory or browse clinics by state.